$3.88
3.74% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US1920051067
Symbol
CDXS

Codexis, Inc. Stock price

$3.88
+0.49 14.45% 1M
+0.18 4.86% 6M
+0.83 27.21% YTD
+1.79 85.65% 1Y
-32.37 89.30% 3Y
-11.18 74.24% 5Y
+1.57 67.97% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.14 3.74%
ISIN
US1920051067
Symbol
CDXS
Industry

Key metrics

Market capitalization $315.75m
Enterprise Value $266.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.14
P/S ratio (TTM) P/S ratio 4.90
P/B ratio (TTM) P/B ratio 4.30
Revenue growth (TTM) Revenue growth -12.86%
Revenue (TTM) Revenue $64.45m
EBIT (operating result TTM) EBIT $-50.73m
Free Cash Flow (TTM) Free Cash Flow $-46.13m
Cash position $90.77m
EPS (TTM) EPS $-0.88
P/E forward negative
P/S forward 4.66
EV/Sales forward 3.91
Short interest 2.68%
Show more

Is Codexis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Codexis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Codexis, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Codexis, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Codexis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
64 64
13% 13%
100%
- Direct Costs 20 20
16% 16%
32%
44 44
12% 12%
68%
- Selling and Administrative Expenses 44 44
20% 20%
69%
- Research and Development Expense 42 42
37% 37%
66%
-43 -43
22% 22%
-66%
- Depreciation and Amortization 8.01 8.01
25% 25%
12%
EBIT (Operating Income) EBIT -51 -51
22% 22%
-79%
Net Profit -62 -62
24% 24%
-96%

In millions USD.

Don't miss a Thing! We will send you all news about Codexis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Codexis, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provid...
Neutral
GlobeNewsWire
3 days ago
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors.
Neutral
GlobeNewsWire
4 days ago
—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enz...
More Codexis, Inc. News

Company Profile

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Head office United States
CEO Stephen Dilly
Employees 174
Founded 2002
Website www.codexis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today